Company: LIMN
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001410578-25-001746
Chunk: 6

Company: Liminatus Pharma, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 6
---
 inability to manage growth effectively; |

| ● | the Company’s ability to recruit, train and retain qualified personnel; |

| ● | estimates for the prospects and financial performance of the Company’s business may prove to be incorrect or materially different from actual results; |

| ● | costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; |

| ● | risks related to the Company’s marketing and growth strategies; |

| ● | the effects of competition on the Company’s business; |

| ● | expectations with respect to future operating and financial performance and growth, including when the Company will generate positive cash flow from operations; |

| ● | the Company’s ability to raise funding on reasonable terms as necessary to develop its products in the timeframe contemplated by its business plan; |

| ● | the inability to maintain the listing of the Company’s common stock and warrants on Nasdaq following the Business Combination; |

5

| ● | other risks and uncertainties indicated in this prospectus, including those under “Risk Factors” beginning on page 14 of this prospectus and other filings that have been made or will be made with the SEC by the Company. |

In addition, there may be events that the Company’s management is not able to predict accurately or over which the Company has no control. Should one or more of these risks or uncertainties materialize or should any of the assumptions made by the management of the Company proves incorrect, actual results may vary in material respects from those projected in these forward-looking statements. All subsequent written and oral forward-looking statements concerning the Company or other matters addressed in this prospectus and attributable to the Company or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this prospectus. Except to the extent required by applicable law or regulation, the Company undertakes no obligation to update these forward-looking statements to reflect events or circumstances after the date of this prospectus or to reflect the occurrence of unanticipated events.

6

<div align='center'>PROSPECTUS SUMMARY</div>

This summary highlights selected information from this prospectus and does not contain all of the information that is important to you in making an investment decision. This summary is qualified in its entirety by the more detailed information included in this prospectus. Before making your investment decision with respect to our securities, you should carefully read this entire prospectus, including the information under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and the financial statements included elsewhere in